Medtronic has secured expanded European CE mark approval for its MiniMed 780G automated insulin delivery system, now authorized for use in patients aged 2 and older—including pregnant individuals—and those with type 2 diabetes.
The decision follows positive results from the LENNY clinical trial, which demonstrated the device’s safety and effectiveness in young children with type 1 diabetes aged 2 to 6 years. Additional data also support benefits for type 2 diabetes patients.
Dr. Fiona Campbell, chair of the U.K.’s National Children & Young People’s Diabetes Network, said the advancement eases the burden of constant glucose monitoring and insulin adjustments, promoting better growth, brain development, sleep, and overall quality of life in children.
Follow MEDWIRE.AI for updates on diabetes technology and regulatory approvals.
